Measuring Renin and Aldosterone in Kidney Injury with Hypertension
Checking renin and aldosterone in a patient with kidney injury and hypertension primarily screens for primary aldosteronism (PA), a treatable cause of secondary hypertension that independently worsens cardiovascular and renal outcomes beyond blood pressure effects alone. This testing is critical because PA carries a 2-fold increased risk of heart failure, 2.8-fold increased stroke risk, and 4-fold increased atrial fibrillation risk compared to primary hypertension, even when blood pressure is matched 1.
What These Tests Tell You
Primary Aldosteronism Screening
The combined interpretation of plasma aldosterone concentration (PAC), plasma renin activity (PRA), and the aldosterone-to-renin ratio (ARR) is the most accurate screening method for PA 1. A positive screen typically shows:
- Suppressed renin activity (<1 ng/mL/h)
- Elevated aldosterone (≥10 ng/dL)
- ARR ≥30 (when aldosterone is in ng/dL and renin in ng/mL/h) 1
Critical Caveat in Kidney Disease
In patients with chronic kidney disease, renin decreases proportionately to nephron loss, which increases false-positive rates for PA screening 2. Aldosterone can also be elevated in CKD, further complicating interpretation 2. The exception is renal artery stenosis, where renin will be elevated despite kidney injury 2.
Interpretation Algorithm
If Renin is Suppressed + Aldosterone Elevated:
- Consider PA as the primary diagnosis - this explains both the hypertension and may be contributing to kidney injury
- PA independently causes kidney damage through aldosterone's direct toxic effects on renal tissue 1, 3
- Recent evidence shows PAC strongly correlates with early renal injury biomarkers (RBP, β2-microglobulin) in PA patients 3
If Renin is Elevated:
- Consider renovascular disease (renal artery stenosis) - renin rises due to renal ischemia despite overall kidney injury 2
- In malignant hypertension with kidney injury, renin can be markedly elevated and correlates with severity of renal dysfunction 4
- Important pitfall: Even in PA patients, severe malignant hypertension with renal failure can cause renin to escape suppression, potentially masking the PA diagnosis 5
If Both are Low-Normal:
- Likely primary (essential) hypertension causing kidney injury
- The kidney injury itself may be suppressing renin through nephron loss 2
Clinical Significance for Outcomes
This testing matters because PA is treatable and treatment improves kidney and cardiovascular outcomes 1. Treatment options include:
- Unilateral adrenalectomy for unilateral disease (one-third of PA cases)
- Mineralocorticoid receptor antagonists (spironolactone/eplerenone) for bilateral disease or non-surgical candidates 1
Research shows that in PA patients, escape of renin from suppression predicts more severe renal damage and less favorable outcomes after treatment 6. Conversely, effective renin-angiotensin system blockade correlates with preserved renal function in high-renin states 7.
Testing Considerations
Optimize testing conditions:
- Normal serum potassium (hypokalemia causes false negatives) 1
- Unrestricted salt intake 1
- Ideally withdraw mineralocorticoid receptor antagonists for 4 weeks 1
Medication effects to know:
- Beta-blockers and central alpha-agonists suppress both renin and aldosterone (can cause false positives) 2, 1
- ACE inhibitors/ARBs stimulate renin and suppress aldosterone 1
- Diuretics stimulate both 1
However, current guidelines support screening despite these medications rather than delaying diagnosis 1. If initial screen is positive on beta-blockers, repeat after 2-week withdrawal if safe 2.
Bottom Line
In your patient with kidney injury and hypertension, renin and aldosterone testing identifies whether excess aldosterone is driving both conditions (PA), whether renovascular disease is present (high renin), or whether this is primary hypertension with secondary kidney damage. Given that PA occurs in 5-10% of all hypertensive patients and 20% of those with resistant hypertension, and that it independently accelerates kidney damage, this screening is essential for preventing progressive renal failure and cardiovascular events 1.